Cytek IPO Presentation Deck

Thought Leadership 1. Cytek is Transforming into a Full Solutions Provider 2 Establish Place instruments at top research universities and corporations across US, Europe and Asia 3. 000 750+ Instrument placements Drive Cutting- Edge Applications Focus on high value areas of scientific research and discovery 210+ Publications Position the Platform for Broad Use H™ Drive placements at pharma, biotech and CRO customers 125+ Biopharma Customers Translate into the Clinical Setting Develop applications for clinical setting using our FSP technology $23Bn Broader Cell Analysis TAM¹ 2024 market projection estimate We define Adjusted EBITDA as net income (loss) adjusted for interest expense, interest income, other income (expense), net, provision for (benefit from) income taxes, depreciation and amortization, legal settlement expenses and stock-based compensation expenses. Adj. EBITDA Margin is on a percentage of revenue basis. For reference, 2020 Adjusted EBITDA was $14.9MM and 2020 Adjusted EBITDA margin was 16% Represents longer term financial objectives of the Company and does not constitute estimates of the Company's future performance, financial, or otherwise. There is no assurance that the Company will ever achieve any of these objectives. See Special Note Regarding Forward-Looking Statements Transformation into Solutions Provider End-to-end solutions provider, including instruments, reagents, software and services Strong and Scaling Adj. EBITDA2,3 CYTEK | 28

View entire presentation